Prognostic Value of Cancer Stem Cell Markers in Head and Neck Squamous Cell Carcinoma: a Meta-analysis.
Prognostic Value of Cancer Stem Cell Markers in Head and Neck Squamous Cell Carcinoma: a Meta-analysis.
复制标题
癌症干细胞标志物在头颈鳞状细胞癌中的预后价值：荟萃分析。
DOI：
10.1038/srep43008
复制
发表时间：
2017-02-21
影响因子：
4.6
通讯作者：
Xia J
中科院分区：
文献类型：
--
作者：
Fan Z;Li M;Chen X;Wang J;Liang X;Wang H;Wang Z;Cheng B;Xia J
Bmi-1、CD 133、Nanog和Oct-4已被报道为头颈部鳞状细胞癌（HNSCC）中的癌症干细胞（CSC）标志物。然而，它们在HNSCC中的预后价值仍存在争议。因此，本荟萃分析旨在评估四种CSC标志物与HNSCC患者生存结局之间的相关性。共有27项研究的22篇文章符合纳入标准，并计算了合并风险比（HR）和95%置信区间（95% CI）。数据分析显示CSC标志物的高表达与较差的总生存期（OS）相关（HR = 1.93，95%CI：1.46-2.55，P <0.001）和无病生存期（DFS）（HR = 4.78，95%CI：2.95-7.75，P <0.001），但对HNSCC患者的疾病特异性生存期（DSS）无影响（HR = 1.17，95%CI：0.74-1.84，P = 0.50）。亚组分析表明，CD133高表达，（HR = 2.33，95%CI：1.42 - 3.83，P <0.001），10月-4日（HR = 2.10，95%CI：1.36 - 3.22，P = 0.007）和Nanog（HR = 2.49，95%CI：1.66-3.72，P <0.001）均能预测HNSCC患者OS的降低，而Bmi-1的过表达与HNSCC患者OS的降低无关（HR = 1.32，95%CI：0.66-2.65，P = 0.43）。因此，我们得出结论，CSC标志物，特别是CD 133，Nanog和Oct-4，可能是HNSCC患者的预测因子。
Bmi-1, CD133, Nanog and Oct-4 have been reported as cancer stem cell (CSC) markers in head and neck squamous cell carcinoma (HNSCC). However, the prognostic value of them in HNSCC remains controversial. Hence, this meta-analysis was conducted to access the association between the four CSC markers and survival outcome of HNSCC patients. A total of 22 articles with 27 studies met the inclusion criteria and the combined hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated. Data analysis showed that high expression of CSC markers was associated with poor overall survival (OS) (HR = 1.93; 95% CI: 1.46–2.55,P< 0.001) and disease free survival (DFS) (HR = 4.78; 95% CI: 2.95–7.75,P< 0.001) but not disease specific survival (DSS) (HR = 1.17; 95% CI: 0.74–1.84,P= 0.50) of HNSCC patients. Subgroup analysis indicted that high expression of CD133 (HR = 2.33, 95%CI: 1.42–3.83,P< 0.001), Oct-4(HR = 2.10, 95%CI: 1.36–3.22,P= 0.007) and Nanog (HR = 2.49, 95%CI: 1.66–3.72,P< 0.001) could predict poor OS in HNSCC patients respectively whereas overexpression of Bmi-1 was not related to the reduced OS in HNSCC patients (HR = 1.32, 95%CI: 0.66–2.65,P= 0.43). Therefore, we concluded that CSC markers, especially CD133, Nanog and Oct-4, might be predictive factors in HNSCC patients.